Effects of photoactivated 5-aminolevulinic acid hexyl ester on MDR1 over-expressing human uterine sarcoma cells

Toxicology Letters

Volumn 181, Issue 1, 2008, Pages 7-12

  Chu, Ellie S M ^a   Yow, Christine M N ^a   Shi, Mark ^b   Ho, Rodney J Y ^b  

^a HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

5 Aminolevulinic acidhexyl ester; MDR1; Multi drug resistance; P glycoprotein; Photodynamic therapy

Indexed keywords

5-AMINOLEVULINIC ACID HEXYL ESTER; ABCB1 PROTEIN, HUMAN; AMINOLEVULINIC ACID; AMINOLEVULINIC ACID HEXYL ESTER; DRUG DERIVATIVE; GLYCOPROTEIN P; MESSENGER RNA; VERAPAMIL;

ARTICLE; DRUG ANTAGONISM; FEMALE; GENETICS; HUMAN; PATHOLOGY; PHOTOCHEMOTHERAPY; PHYSIOLOGY; SARCOMA; TUMOR CELL LINE; UTERUS CANCER;

AMINOLEVULINIC ACID; CELL LINE, TUMOR; FEMALE; HUMANS; P-GLYCOPROTEIN; PHOTOCHEMOTHERAPY; RNA, MESSENGER; SARCOMA; UTERINE NEOPLASMS; VERAPAMIL;

EID: 56149092273     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2008.06.860     Document Type: Article

References (29)

1. Annereau, J.P., Szakacs, G., Tucker, C.J., Arciello, A., Cardarelli, C., Collins, J., Grissom, S., Zeeberg, B.R., Reinhold, W., Weinstein, J.N., Pommier, Y., Paules, R.S., Gottesman, M.M., 2004. Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by amicroarray dedicated to multidrug resistance. Mol. Pharmacol. 66, 1397-1405.
2. Calzavara-Pinton, P.G., Venturini, M., Sala, R., 2007. Photodynamic therapy: update 2006. Part 1. Photochemistry and photobiology. J. Eur. Acad. Dermatol. Venereol. 21, 293-302.
3. Casas, A., Fukuda, H., Di, V.G., Batlle, A., 2001. Photosensitization and mechanism of cytotoxicity induced by the use of ALA derivatives in photodynamic therapy. Br. J. Cancer 85, 279-284.
4. Chu, E.S., Wu, R.W., Yow, C.M., Wong, T.K., Chen, J.Y., 2006. The cytotoxic and genotoxic potential of 5-aminolevulinic acid on lymphocytes: a comet assay study. Cancer Chemother. Pharmacol. 58, 408-414.
5. Chu, E.S., Wong, T.K., Yow, C.M., 2008. Photodynamic effect in medulloblastoma: downregulation of matrix metalloproteinases and human telomerase reverse transcriptase expressions. Photochem. Photobiol. Sci. 7, 76-83.
6. Dougherty, T.J., Gomer, C.J., Henderson, B.W., Jori, G., Kessel, D., Korbelik, M., Moan, J., Peng, Q., 1998. Photodynamic therapy. J. Natl. Cancer Inst. 90, 889-905.
7. Fotinos, N., Campo, M.A., Popowycz, F., Gurny, R., Lange, N., 2006. 5-Aminolevulinic acid derivatives in photomedicine: characteristics, application and perspectives. Photochem. Photobiol. 82, 994-1015.
8. Godal, A., Nilsen, N.O., Klaveness, J., Branden, J.E., Nesland, J.M., Peng, Q., 2006. New derivatives of 5-aminolevulinic acid for photodynamic therapy: chemical synthesis and porphyrin production in in vitro and in vivo biological systems. J. Environ. Pathol. Toxicol. Oncol. 25, 109-126.
9. Gottesman, M.M., 2002. Mechanisms of cancer drug resistance. Annu. Rev. Med. 53, 615-627.
10. Harker, W.G., Sikic, B.I., 1985. Multidrug (pleiotropic) resistance in doxorubicinselected variants of the human sarcoma cell line MES-SA. Cancer Res. 45, 4091-4096.
11. Li, W., Zhang, W.J., Ohnishi, K., Yamada, I., Ohno, R., Hashimoto, K., 2001. 5-Aminolaevulinic acid-mediated photodynamic therapy in multidrug resistant leukemia cells. J. Photochem. Photobiol. B 60, 79-86.
12. Moan, J., Peng, Q., 2003. An outline of the hundred-year history of PDT. Anticancer Res. 23, 3591-3600.
13. Ozols, R.F., Cunnion, R.E., Klecker Jr., R.W., Hamilton, T.C., Ostchega, Y., Parrillo, J.E., Young, R.C., 1987. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J. Clin. Oncol. 5, 641-647.
14. Palumbo, G., 2007. Photodynamic therapy and cancer: a brief sightseeing tour. Expert. Opin. Drug Deliv. 4, 131-148.
15. Pandey, R.K., Goswami, L.N., Chen, Y.,Gryshuk,A., Missert, J.R., Oseroff,A., Dougherty, T.J., 2006. Nature: a rich source for developing multifunctional agents. Tumorimaging and photodynamic therapy. Lasers Surg. Med. 38, 445-467.
16. Qiang, Y.G., Yow, C.M., Huang, Z., 2008. Combination of photodynamic therapy and immunomodulation: current status and future trends. Med. Res. Rev. 28, 632-644.
17. Robey, R.W., Steadman, K., Polgar, O., Bates, S.E., 2005. ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy. Cancer Biol. Ther. 4, 187-194.
18. Rossi, F.M., Campbell, D.L., Pottier, R.H., Kennedy, J.C., Dickson, E.F., 1996. In vitro studies on the potential use of 5-aminolaevulinic acid-mediated photodynamic therapy for gynaecological tumours. Br. J. Cancer 74, 881-887.
19. Solban, N., Rizvi, I., Hasan, T., 2006. Targeted photodynamic therapy. Lasers Surg. Med. 38, 522-531.
20. Thomas, H., Coley, H.M., 2003.Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 10, 159-165.
21. Tsai, T., Hong, R.L., Tsai, J.C., Lou, P.J., Ling, I.F., Chen, C.T., 2004. Effect of 5-aminolevulinic acid-mediatedphotodynamic therapy onMCF-7 andMCF-7/ADR cells. Lasers Surg. Med. 34, 62-72.
22. Wesolowska, O., Paprocka, M., Kozlak, J., Motohashi, N., Dus, D., Michalak, K., 2005. Human sarcoma cell lines MES-SA and MES-SA/Dx5 as a model for multidrug resistance modulators screening. Anticancer Res. 25, 383-389.
23. Wu, R.W., Chu, E.S., Yow, C.M., Chen, J.Y., 2006. Photodynamic effects on nasopharyngeal carcinoma (NPC) cells with 5-aminolevulinic acid or its hexyl ester. Cancer Lett. 242, 112-119.
24. Yahanda, A.M., Alder, K.M., Fisher, G.A., Brophy, N.A., Halsey, J., Hardy, R.I., Gosland, M.P., Lum, B.L., Sikic, B.I., 1992. Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J. Clin. Oncol. 10, 1624-1634.
25. Yang, Z.,Woodahl, E.L.,Wang, X.Y., Bui, T., Shen, D.D., Ho, R.J., 2002. Semi-quantitative RT-PCR method to estimate full-length mRNA levels of the multidrug resistance gene. Biotechniques 33, 196-200.
26. Yow, C.M., Mak, N.K., Szeto, S., Chen, J.Y., Lee, Y.L., Cheung, N.H., Huang, D.P., Leung, A.W., 2000a. Photocytotoxic and DNA damaging effect of temoporfin (mTHPC) and merocyanine 540 (MC540) on nasopharyngeal carcinoma cell. Toxicol. Lett. 115, 53-61.
27. Yow, C.M., Chen, J.Y., Mak, N.K., Cheung, N.H., Leung, A.W., 2000b. Cellular uptake, subcellular localization and photodamaging effect of temoporfin (mTHPC) in nasopharyngeal carcinoma cells: comparison with hematoporphyrin derivative (HPD). Cancer Lett. 157, 123-131.
28. Yow, C.M.,Wong, C.K., Huang, Z., Ho, R.J., 2007. Study of the efficacy and mechanism of ALA-mediated photodynamic therapy on human hepatocellular carcinoma cell. Liver Int. 27, 201-208.
29. Yow, C.M., Leung, A.W., Huang, Z., 2008. mTHPC-photodynamic therapy induced apoptosis in nasopharyngeal carcinoma cells. Proc. SPIE 6826, 75-80.